Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH176 in Mitochondrial Disease (KHENERGY)
NCT02909400Phase 2Completed
- Sponsor
- Khondrion
- Start
- Sep 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonlicromanol in mitochondrial disease, mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes and deafness (MIDD) (2 arms), sponsored by Khondrion. Primary endpoint: Movement disorders at 1 month. Started Sep 2016; status: completed.
02
Drugs
sonlicromanol
03
Conditions
mitochondrial diseasemitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS)maternally inherited diabetes and deafness (MIDD)
Beyond the preview
Go deeper on NCT02909400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909400.